vs
Side-by-side financial comparison of FRANKLIN STREET PROPERTIES CORP (FSP) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
FRANKLIN STREET PROPERTIES CORP is the larger business by last-quarter revenue ($26.0M vs $18.6M, roughly 1.4× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs -28.1%, a 93.9% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -8.2%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -8.7%).
Franklin Street Properties Corp is a Massachusetts-based real estate investment trust (REIT) in the United States. It primarily invests in, owns, and operates high-quality office properties across major U.S. metropolitan markets, serving corporate tenants across various industry segments, and delivers stable long-term returns via rental income and strategic asset management.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
FSP vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.0M | $18.6M |
| Net Profit | $-7.3M | $12.3M |
| Gross Margin | 59.4% | — |
| Operating Margin | -27.9% | 56.3% |
| Net Margin | -28.1% | 65.7% |
| Revenue YoY | -8.2% | 1808.5% |
| Net Profit YoY | 14.1% | 376.5% |
| EPS (diluted) | $-0.06 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.0M | $18.6M | ||
| Q3 25 | $27.3M | $334.0K | ||
| Q2 25 | $26.7M | $1.4M | ||
| Q1 25 | $27.1M | $257.0K | ||
| Q4 24 | $28.4M | $977.0K | ||
| Q3 24 | $29.7M | $660.0K | ||
| Q2 24 | $30.8M | $736.0K | ||
| Q1 24 | $31.2M | $1.4M |
| Q4 25 | $-7.3M | $12.3M | ||
| Q3 25 | $-8.3M | $-8.6M | ||
| Q2 25 | $-7.9M | $-6.9M | ||
| Q1 25 | $-21.4M | $-5.4M | ||
| Q4 24 | $-8.5M | — | ||
| Q3 24 | $-15.6M | $-2.8M | ||
| Q2 24 | $-21.0M | $-14.5M | ||
| Q1 24 | $-7.6M | $411.0K |
| Q4 25 | 59.4% | — | ||
| Q3 25 | 60.9% | — | ||
| Q2 25 | 59.9% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 59.7% | — | ||
| Q3 24 | 61.0% | — | ||
| Q2 24 | 64.2% | — | ||
| Q1 24 | 64.7% | — |
| Q4 25 | -27.9% | 56.3% | ||
| Q3 25 | -30.5% | -2516.5% | ||
| Q2 25 | -29.2% | -701.0% | ||
| Q1 25 | -78.9% | -3350.2% | ||
| Q4 24 | -29.9% | — | ||
| Q3 24 | -52.4% | -1563.6% | ||
| Q2 24 | -68.0% | -1255.0% | ||
| Q1 24 | -24.0% | -692.5% |
| Q4 25 | -28.1% | 65.7% | ||
| Q3 25 | -30.5% | -2572.2% | ||
| Q2 25 | -29.5% | -504.8% | ||
| Q1 25 | -79.1% | -2097.7% | ||
| Q4 24 | -30.0% | — | ||
| Q3 24 | -52.6% | -425.5% | ||
| Q2 24 | -68.2% | -1964.4% | ||
| Q1 24 | -24.2% | 29.9% |
| Q4 25 | $-0.06 | $0.25 | ||
| Q3 25 | $-0.08 | $-0.17 | ||
| Q2 25 | $-0.08 | $-0.14 | ||
| Q1 25 | $-0.21 | $-0.11 | ||
| Q4 24 | $-0.09 | — | ||
| Q3 24 | $-0.15 | $-0.06 | ||
| Q2 24 | $-0.20 | $-0.30 | ||
| Q1 24 | $-0.07 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $30.6M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $607.0M | $49.4M |
| Total Assets | $892.9M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.6M | $40.0M | ||
| Q3 25 | $31.4M | $37.9M | ||
| Q2 25 | $29.4M | $44.8M | ||
| Q1 25 | $30.2M | $40.6M | ||
| Q4 24 | $41.1M | $59.3M | ||
| Q3 24 | $40.9M | $68.8M | ||
| Q2 24 | $30.2M | $73.0M | ||
| Q1 24 | $34.2M | $80.2M |
| Q4 25 | $607.0M | $49.4M | ||
| Q3 25 | $615.3M | $36.4M | ||
| Q2 25 | $624.7M | $44.5M | ||
| Q1 25 | $633.4M | $50.5M | ||
| Q4 24 | $655.9M | $55.1M | ||
| Q3 24 | $665.4M | $58.5M | ||
| Q2 24 | $682.1M | $60.4M | ||
| Q1 24 | $703.9M | $74.1M |
| Q4 25 | $892.9M | $59.0M | ||
| Q3 25 | $901.0M | $51.1M | ||
| Q2 25 | $903.2M | $60.7M | ||
| Q1 25 | $916.4M | $67.9M | ||
| Q4 24 | $946.9M | $90.6M | ||
| Q3 24 | $981.5M | $99.0M | ||
| Q2 24 | $1.0B | $107.8M | ||
| Q1 24 | $1.0B | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.8M | $18.4M |
| Free Cash FlowOCF − Capex | $-12.7M | — |
| FCF MarginFCF / Revenue | -48.6% | — |
| Capex IntensityCapex / Revenue | 63.0% | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $-25.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.8M | $18.4M | ||
| Q3 25 | $8.3M | $-8.7M | ||
| Q2 25 | $-2.9M | $-7.5M | ||
| Q1 25 | $-5.5M | $-7.5M | ||
| Q4 24 | $9.0M | $-24.0M | ||
| Q3 24 | $14.5M | $765.0K | ||
| Q2 24 | $-648.0K | $-10.9M | ||
| Q1 24 | $-7.1M | $-4.0M |
| Q4 25 | $-12.7M | — | ||
| Q3 25 | $3.0M | — | ||
| Q2 25 | $-5.7M | — | ||
| Q1 25 | $-9.9M | — | ||
| Q4 24 | $-16.2M | — | ||
| Q3 24 | $8.6M | — | ||
| Q2 24 | $-5.1M | — | ||
| Q1 24 | $-15.8M | — |
| Q4 25 | -48.6% | — | ||
| Q3 25 | 11.0% | — | ||
| Q2 25 | -21.5% | — | ||
| Q1 25 | -36.7% | — | ||
| Q4 24 | -57.2% | — | ||
| Q3 24 | 29.1% | — | ||
| Q2 24 | -16.7% | — | ||
| Q1 24 | -50.8% | — |
| Q4 25 | 63.0% | — | ||
| Q3 25 | 19.4% | — | ||
| Q2 25 | 10.7% | — | ||
| Q1 25 | 16.4% | — | ||
| Q4 24 | 88.9% | — | ||
| Q3 24 | 19.6% | — | ||
| Q2 24 | 14.6% | — | ||
| Q1 24 | 28.1% | — |
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FSP
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
